Genprex Provides Forward Looking Guidance and Updates on Corporate Activities, Publishes New Corporate Deck
September 03 2019 - 8:00AM
Business Wire
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy
company, today announced anticipated milestones and future guidance
on its clinical development programs, manufacturing and strategy
for bringing its lead drug candidate, Oncoprex™ immunogene therapy,
to market.
These anticipated milestones and future guidance are
incorporated into the latest update of the company’s corporate
presentation, which can be found on the company’s website.
“These milestones emphasize our commitment to developing
potentially life-changing gene technologies for cancer patients who
need them most,” said Rodney Varner, Chairman and Chief Executive
Officer of Genprex. “We continue to dedicate our efforts toward
developing Oncoprex for non-small cell lung cancer (“NSCLC”) and we
believe that achievement of these milestones will enable us to
advance our gene therapy platform and position us to bring our drug
candidate to commercialization.”
Anticipated milestones and future
guidance:
2H 2019
- Establish scalability parameters of new, optimized
manufacturing method for lipid nanoparticle delivery system as part
of new Genprex research and development program
- Complete protocol for Oncoprex + immunotherapy clinical
trial
- Prepare and file IND for Oncoprex + immunotherapy clinical
trial
- Determine clinical site selection, expansion strategy and
contract with clinical sites for Oncoprex + erlotinib clinical
trial
1H 2020
- Complete manufacturing scale-up to support trial site expansion
and commercial-scale development
- Complete preparation of lipid nanoparticle delivery system and
TUSC2 DNA plasmid for clinical expansion
- Contract with new clinical trial sites for Oncoprex +
immunotherapy clinical trial
- Begin enrolling patients at new clinical sites for Oncoprex +
immunotherapy clinical trial
In addition to the milestone updates, Genprex also unveiled in
its updated corporate presentation, an overview of the limitations
to current NSCLC treatment and a swimmer plot demonstrating results
to date of its Phase I/II clinical trial administering Oncoprex in
combination with erlotinib against NSCLC. Genprex also recently
launched a new interactive timeline on its website where visitors
can follow the company’s success since its inception.
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer
patients, based upon a unique proprietary technology platform,
including Genprex’s initial product candidate, Oncoprex™ immunogene
therapy for non-small cell lung cancer (NSCLC). Genprex’s platform
technologies are designed to administer cancer fighting genes by
encapsulating them into nanoscale hollow spheres called
nanovesicles, which are then administered intravenously and taken
up by tumor cells where they express proteins that are missing or
found in low quantities. Oncoprex has a multimodal mechanism of
action whereby it interrupts cell signaling pathways that cause
replication and proliferation of cancer cells, re-establishes
pathways for apoptosis, or programmed cell death, in cancer cells,
and modulates the immune response against cancer cells. Oncoprex
has also been shown to block mechanisms that create drug
resistance. For more information, please visit the company’s web
site at www.genprex.com or follow Genprex on Twitter, Facebook and
LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
our stated milestones and our ability to advance the clinical
development, manufacturing and commercialization of our product
candidates, and the effects of Oncoprex on cancer. Risks and
uncertainties that contribute to the uncertain nature of the
forward-looking statements include our ability to achieve our
stated milestones, the timing and effect of our achieving those
milestones, and of other factors, on the clinical development,
manufacturing and commercialization of our product candidates, the
presence and level of TUSC2’s effect on cancer, the timing and
success of our clinical trials and planned clinical trials of TUSC2
and Oncoprex™ and our other potential product candidates and the
timing and success of obtaining FDA approval of Oncoprex™ and our
other potential product candidates. These and other risks and
uncertainties are described more fully under the caption “Risk
Factors” and elsewhere in our filings and reports with the United
States Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. We undertake no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190903005044/en/
Genprex, Inc. (877) 774-GNPX (4679)
Investor Relations GNPX Investor Relations (877) 774-GNPX
(4679) ext. #2 investors@genprex.com
Media Contact Genprex Media Relations Kalyn Dabbs (877)
774-GNPX (4679) ext. #3 media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024